Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemiaMelanie Sulda, Bryone J. Kuss, Catherine A. Abbott et al.|Cancer Biology & Therapy|2010Cited by 28
A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and ToxicityStephen P. Mulligan, Bryone J. Kuss, Melanie Sulda et al.|Blood|2014Cited by 21
A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 StudyStephen P. Mulligan, Bryone J. Kuss, Devinder Gill et al.|Blood|2012Cited by 14
Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemiaMelanie Sulda, Peter J. Macardle, Bryone J. Kuss et al.|Internal Medicine Journal|2010Cited by 6
Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)Stephen P. Mulligan, Bryone J. Kuss, Devinder Gill et al.|Blood|2014Cited by 5